Novo Nordisk launches oral Ozempic in US pharmacies, faces Q1 earnings test amid margin concerns, and prepares obesity pipeline data for May.<\/p>\n
The Danish pharmaceutical heavyweight is entering a defining stretch. On Monday, Novo Nordisk\u2019s oral version of Ozempic hits the shelves of more than 70,000 US pharmacies, marking a strategic push to convert injection-weary patients and fortify its grip on the weight-loss market. By Wednesday, the company will unveil first-quarter earnings that investors hope will clarify whether margins can withstand the ramp-up in production costs.<\/p>\n
A Calculated Rollout<\/p>\n
Novo Nordisk is leaving little to chance with the launch. The pill is available in three dosages, with aggressive pricing designed to undercut competitors and drive rapid adoption. For insured patients, a three-month supply often costs just $25 out of pocket. Uninsured individuals and those on Medicare can access the starter dose for $149 per month. To ensure broad distribution, the company has inked partnerships with WW International and the discount platform GoodRx.<\/p>\n
The timing is no accident. The Food and Drug Administration proposed on Friday to remove semaglutide and similar GLP-1 drugs from compounding exemptions, a move that would effectively ban cheap copycat versions that proliferated during supply shortages. If enacted, the decision shields Novo Nordisk\u2019s exclusive market position and could ease the pricing pressure that has weighed on the sector.<\/p>\n
Earnings Under the Microscope<\/p>\n
Wall Street expects first-quarter revenue of approximately $11.35 billion and earnings per share of $0.87. The spotlight, however, will be on net margins, which recently stood at just over 33%. Higher manufacturing costs tied to the new tablet formulations threaten to compress profitability, and analysts will scrutinize management\u2019s guidance during Wednesday\u2019s conference call at 1:00 PM European time.<\/p>\n
Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\n The stock has had a rough start to the year, sliding roughly 19% since January. A late-week rally on Friday, fueled by the FDA news, lifted shares 4% to \u20ac35.95 in European trading. In dollar terms, the stock closed at $43.88, posting a weekly gain of nearly 7%. Despite the bounce, the valuation has compressed sharply: the price-to-earnings ratio now sits at 12.4, while the relative strength index of 23 signals an oversold condition.<\/p>\n Pipeline Firepower<\/p>\n Beyond the quarterly numbers, the company is preparing a major data dump. At the European Congress on Obesity in Istanbul in mid-May, Novo Nordisk will present 52 abstracts covering its next-generation obesity pipeline. Key highlights include results for a high-dose 7.2-milligram version of Wegovy, updated data on the CagriSema combination therapy, and analyses of the oral 25-milligram Wegovy pill.<\/p>\n These studies form the scientific foundation for the company\u2019s future growth, and positive readouts could provide a much-needed catalyst for the stock.<\/p>\n